IAE0972+Capecitabine
Phase 3Biologic
IAE0972+Capecitabine is one of 35 biologic programs targeting Clinical Trial. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
34
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
136 competitors in Clinical Trial
#DrugCompanyPhaseTrials
1Gemzar
Johnson & JohnsonPhase 3
Venclexta
AbbViePhase 3
Avelox
BayerPhase 3
Paraplatin
AAvyxa
Phase 3
Opzelura
DDizal Pharmaceuticals
Phase 3
Potassium Iodide
MMeda Pharmaceuticals
Phase 3
Ablysinol
CSL BehringPhase 3
Nascobal
GGrupo Espanol de Tumores Neuroendocrinos
Phase 3
Inlyta
PPrism Pharmaceuticals
Phase 2
Grafapex
MMedexus Pharma, Inc.
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for IAE0972+Capecitabine. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details